Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11953028 | 0.87 | ALDH1A1 (0.44) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL13304332 | 0.87 | DCTPP1 (0.42) | DCTPP1ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL11943240 | 0.83 | DCTPP1 (0.45) | DCTPP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL13329325 | 0.81 | ALDH1A1 (0.51) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL11943222 | 0.80 | DCTPP1 (0.51) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL11946579 | 0.79 | ALDH1A1 (0.36) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL11943226 | 0.78 | DCTPP1 (0.44) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL11943117 | 0.74 | ALDH1A1 (0.47) | DCTPP1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL13329623 | 0.74 | ALDH1A1 (0.41) | DCTPP1ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL11943132 | 0.74 | MAPT (0.46) | DCTPP1ALDH1A1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | DCTPP1 625/4885ALDH1A1 2437/4885MAPT 2295/4885 |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | DCTPP1 209/4885ALDH1A1 2003/4885MAPT 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.